Photograph of Chiemi Suzuki View LinkedIn page Download V-card

Chiemi Suzuki

Senior Counsel

csuzuki@crowell.com
Phone: +1 213.443.5539
515 South Flower St., 40th Floor
Los Angeles, CA 90071-2201

Chiemi Suzuki is a patent litigator in the Los Angeles office of Crowell & Moring. As a senior counsel in the Intellectual Property Group, Chiemi litigates patent cases in the life sciences field, with a particular focus on disputes under the Hatch-Waxman Act, representing pharmaceutical companies at the trial and appellate levels. Chiemi was recognized as a 2014 - 2017 “Rising Star” in intellectual property litigation by Super Lawyers Magazine, New York Metro edition.

Chiemi handles all aspects of patent litigation, from pre-suit investigations, through discovery, Markman proceedings, summary judgment motions, trials, and appeals. Her experience litigating Hatch-Waxman cases on behalf of both generic (first filers and later filers) and innovator pharmaceutical companies gives her unique perspective on the drug-approval provisions under the Federal Food, Drug, and Cosmetic Act. This insight provides her with the ability to develop and implement pragmatic case strategies and case management plans. Chiemi's experience includes litigating the patents covering the drug products Kyprolis® (carfilzomib), Minivelle® (estradiol transdermal system), Embeda® (morphine sulfate and naltrexone hydrochloride), Dexilant® (dexlansoprazole), Fentora® (fentanyl citrate), Adderall XR® (mixed amphetamine salts), and Carbatrol® (carbamazepine), among others.

Prior to joining Crowell & Moring, Chiemi was an associate at an intellectual property firm, where her practice focused on patent litigation under the Hatch-Waxman Act. Before that, Chiemi worked in technology transfer at the Office of Industrial Liaison at Mount Sinai School of Medicine. She has also performed research in the areas of biology and chemical engineering. The results of her research are published in the journal Langmuir.

Chiemi also maintains an active pro bono practice. Chiemi, along with trial co-counsel, received Public Justice’s 2015 Trial Lawyer of the Year Award for her work representing plaintiffs in a five-week federal human trafficking, Civil Rights Act, and RICO jury trial, which resulted in a $14 million verdict, the largest jury award for labor trafficking in U.S. history.

Chiemi earned her B.A. in Biology with a minor in the History of Art from Bryn Mawr College and her M.A. in Biotechnology from Columbia University. She received her J.D. from the University of California, Hastings College of the Law where she was a member of the Hastings Communication and Entertainment Law Journal (Comm/Ent) and earned the CALI Excellence for the Future Award and Witkin Award for Academic Excellence in Alternative Dispute Resolution.

Chiemi is admitted to the California and New York bars. She is a member of the bar of the Supreme Court of the United States and the United States Court of Appeals for the Federal Circuit, as well as various federal district courts.

Representative matters include the following:

  • Degui Chen, Ph.D. v. Michael E. Jung, Ph.D. & Charles L. Sawyers, M.D., No. 2:18-2015 (C.D. Cal.). Representing defendant inventors in an action for correction of inventorship concerning patents that cover Erleada® (apalutamide). 
  • Onyx Therapeutics, Inc. v. Breckenridge Pharmaceutical, Inc., Nos. 16-1001, 18-262, and 19-71 (D. Del.). Represented Breckenridge in a patent infringement case concerning Breckenridge's ANDA for a generic version of Kyprolis® (carfilzomib).
  • Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., Nos. 15-249, 16-465, and 18-758 (D. Del.). Represented Actavis in patent infringement cases concerning Actavis's ANDA for a generic version of Minivelle® (estradiol transdermal system).
  • Pfizer Inc. et al. v. Actavis Laboratories FL, Inc., No. 11-914 (D. Del.). Represented Actavis in a patent infringement case concerning Actavis's ANDA for a generic version of Embeda® (morphine sulfate and naltrexone hydrochloride).
  • Takeda Pharmaceutical Co., Ltd. et al. v. Handa Pharmaceuticals, LLC and Par Pharmaceutical, Inc., No. 3:11-840 (N.D. Cal.), and Par Pharmaceutical, Inc. and Handa Pharmaceuticals, LLC v. Takeda Pharmaceutical Co., Ltd. et al., No. 5:13-1927 (N.D. Cal.). Represented Handa and Par in patent infringement cases concerning Par's ANDA for a generic version of Dexilant® (dexlansoprazole).
  • Cephalon Inc.  v. Watson Pharmaceuticals, Inc. et al., Nos. 08-330 and 09-724 (D. Del.).  Represented Watson in a patent infringement case concerning Watson's ANDA for a generic version of Fentora® (fentanyl citrate).
  • Global-Tech Appliances, Inc. v. SEB S.A., No. 10-6. Counsel of Record for the Federal Circuit Bar Association in a Brief of Amicus Curiae before the Supreme Court concerning the legal standard for the state of mind element of a claim for actively inducing infringement under 35 U.S.C. § 271(b).
  • Shire LLC v. Sandoz, Inc., No. 2009-1180 (Fed. Cir.). Represented appellee in an interlocutory appeal concerning whether stare decisis applies to a previous court's unappealed claim construction decision.

Education

  • Bryn Mawr College, B.A. Biology (2000)
  • University of California, Hastings College of the Law, J.D. (2003)
  • Columbia University, M.A. Biotechnology (2004)

Affiliations

Bar Admissions
California
New York
Southern District of New York
Eastern District of New York
Central District of California
Northern District of California
U.S. Court of Appeals for the Federal Circuit
U.S. Supreme Court

Professional Affiliations
Federal Circuit Bar Association
New York Intellectual Property Law Association
American Bar Association 

View More

Crowell & Moring Elects Eight New Partners and Promotes Seven to Senior Counsel and 26 to Counsel Positions (Jan.02.2020)
Firm News / Announcement
LITIGATION NOTE: Crowell & Moring Client Agilent Successfully Rebuts Preliminary Injunction Because Patent Likely Invalid (Oct.04.2019)
Firm News / Announcement
Super Lawyers Recognizes 79 Crowell & Moring Lawyers Across United States (Oct.31.2017)
Firm News / Announcement
Super Lawyers Recognizes 71 Crowell & Moring Lawyers Across United States (Nov.30.2016)
Firm News / Announcement
"Recovery Claims: A New Source Of University Funding," Law360 (May 11, 2016). Authors: Laurel Pyke Malson, Daniel A. Sasse, Chiemi Suzuki, and Kathryn L. Clune.
Publication
Crowell & Moring Recognized by the Financial Times as One of 2015’s Most Innovative Law Firms in North America (Dec.08.2015)
Firm News / Announcement
Super Lawyers Recognizes 90 Crowell & Moring Attorneys (Oct.27.2015)
Firm News / Announcement
"The Long and Winding Road for BIOSIMILARS: Charting a Pathway through Patent, FDA, Antitrust, Prescription Filling, Reimbursement and Liability Law," Bloomberg BNA Pharmaceutical Law & Industry Report (September 18, 2015). Authors: Chiemi Suzuki, Deborah H. Yellin, Barbara H. Ryland, Lauren B. Patterson, and John Fuson.
Publication
Crowell & Moring Receives Two American Lawyer 'Global Legal Awards' for Global Dispute of the Year in U.S. Litigation and Pro Bono (Jul.27.2015)
Firm News / Announcement
Crowell & Moring's David v. Signal Team Named "Trial Team of the Year" by Public Justice (Jul.15.2015)
Firm News / Announcement

For all Highlights, News & Knowledge, please click here to view desktop bio.

Crowell & Moring LLP is an international law firm with more than 500 lawyers representing clients in litigation and arbitration, regulatory, and transactional matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation, as well as its ongoing commitment to pro bono service and diversity. The firm has offices in Washington, DC, New York, Los Angeles, San Francisco, Orange County, London, and Brussels.

View Desktop Site | Mobile Sitemap

Contact | Subscribe | Terms of Use | Privacy Statement | Alumni

© Crowell & Moring LLP 2020
Attorney advertising - prior results do not guarantee a similar outcome.